Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates

IntroductionAntibody-drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications.Material and methodsIn this article, we performed a deep analysis of their clinical landscape matched with public genomic human datasets from tumour antigen...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2023-09, Vol.13 (9), p.e1329-e1329
Main Authors: Nieto‐Jiménez, Cristina, Sanvicente, Adrián, Díaz‐Tejeiro, Cristina, Moreno, Víctor, lopez de Sá, Alfonso, Calvo, Emiliano, Martínez‐López, Joaquín, Pérez‐Segura, Pedro, Ocaña, Alberto
Format: Article
Language:English
Subjects:
ADC
Antibodies
Cancer
clinical approach
Clinical medicine
Clinical trials
Gene expression
Hematology
Leukemia
Lymphoma
Multiple myeloma
new therapies
Review
Reviews
targeted therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionAntibody-drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications.Material and methodsIn this article, we performed a deep analysis of their clinical landscape matched with public genomic human datasets from tumour antigen targets (TATs), to identify empty areas for clinical development.ResultsWe observed that TATs used in haematological malignancies were more specific than the ones developed in solid cancers. Those included CD19, CD22, CD30, CD33 and CD79b. In solid tumours, we identified TATs, with approved ADCs, widely expressed in non-explored niche indications like Enfortumab vedotin (anti-Nectin4) in lung or cervical cancer; Tisotumab vedotin (anti-TF) in glioblastoma or pancreatic cancer; and Sacituzumab govitecan (anti-TROP2) in pancreatic, gastric, thyroid or endometrial cancer, among others. Similarly, niche indications for ADCs in clinical development included targets for CD71, PSMA, PTK7 or CD74, in tumours like breast, lung, stomach or colon. Some of these TATs were essential for the survival of tumour cells like CD71, PSMA and PTK7.ConclusionsIn summary, our study opens the door for further evaluation of ADCs in several indications not explored before.
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.1329